GCM
BCYC

Goldstream Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Goldstream Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-48,257
Closed -$2.94M – 20
2021
Q4 		$2.94M Buy
+48,257
New +$2.66M 0.72% 15

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldstream Capital Management's BCYC Position: Q1 2022 in Review

Goldstream Capital Management sold out of Bicycle Therapeutics (BCYC) in Q1 2022, closing a stake of 48,257 shares — an estimated $2.94M sold.

Goldstream Capital Management first reported a position in BCYC in Q4 2021 and held it in 1 quarter. The position peaked at $2.94M in Q4 2021. 105 funds tracked by Wall St. Rank hold BCYC as of Q1 2022.

  • Goldstream Capital Management reported no remaining Bicycle Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Goldstream Capital Management sold 48,257 Bicycle Therapeutics shares in Q1 2022, an estimated $2.94M.
  • Goldstream Capital Management first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 1 quarter.
  • Goldstream Capital Management's Bicycle Therapeutics position peaked at $2.94M in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2022.

Based on Goldstream Capital Management's 13F filing for Q1 2022, filed 13 May 2022.